Cancer Letters
Volume 297, Issue 1 , Pages 75-83 , 1 November 2010

Sodium dichloroacetate (DCA) reduces apoptosis in colorectal tumor hypoxia

Received 20 January 2010 ,Revised 6 April 2010 ,Accepted 15 April 2010.

References 

  1. Stacpoole PW, Nagaraja NV, Hutson AD. Efficacy of dichloroacetate as a lactate-lowering drug. J. Clin. Pharmacol. 2003;43:683–691
  2. Stacpoole PW, Kurtz TL, Han Z, Langaee T. Role of dichloroacetate in the treatment of genetic mitochondrial diseases. Adv. Drug Deliv. Rev. 2008;60:1478–1487
  3. McFate T, Mohyeldin A, Lu H, Thakar J, Henriques J, Halim ND, et al. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J. Biol. Chem. 2008;283:22700–22708
  4. Xu R, Pelicano H, Zhou Y, Carew J, Feng L, Bhalla K, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005;65:613–621
  5. Berridge MV, Herst PM, Lawen A. Targeting mitochondrial permeability in cancer drug development. Mol. Nutr. Food Res. 2009;53:76–86
  6. Pedersen PL. The cancer cell’s “power plants” as promising therapeutic targets: an overview. J. Bioenergy Biomembr. 2007;39:1–12
  7. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25:4633–4646
  8. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007;11:37–51
  9. Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Brit. J. Cancer. 2008;99:989–994
  10. J.G. Pan, T.W. Mak, Metabolic targeting as an anticancer strategy: dawn of a new era? Sci. STKE Apr 10 (381) (2007) 14.
  11. Wong JY, Huggins GS, Debidda M, Munshi NC, De Vivo I. Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol. Oncol. 2008;109:394–402
  12. Cao W, Yacoub S, Shiverick KT, Namiki K, Sakai Y, Porvasnik S, et al. Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate. 2008;68:1223–1231
  13. Sun RC, Fadia M, Dahlstrom JE, Parish CR, Board PG, Blackburn AC. Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res. Treat. 2010;120:253–260
  14. Cairns RA, Bennewith KL, Graves EE, Giaccia AJ, Chang DT, Denko NC. Pharmacologically increased tumor hypoxia can be measured by 18F-Fluoroazomycin arabinoside positron emission tomography and enhances tumor response to hypoxic cytotoxin PR-104. Clin. Cancer Res. 2009;15:7170–7174
  15. Chen Y, Cairns R, Papandreou I, Koong A, Denko NC. Oxygen consumption can regulate the growth of tumors a new perspective on the Warburg effect. PLoS One. 2009;4:e7033
  16. Pearson H. Cancer patients opt for unapproved drug. Nature. 2007;446:474–475
  17. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov. 2007;6:273–286
  18. Rmali KA, Puntis MCA, Jiang WG. Tumor-associated angiogenesis in human colorectal cancer. Colorectal Dis. 2006;9:3–14
  19. Raghunand N, Gatenby RA, Gillies RJ. Microenvironmental and cellular consequences of altered blood flow in tumours. Brit. J. Radiol. 2003;76:S11–S22
  20. Jain RK. Molecular regulation of vessel maturation. Nat. Med. 2003;9:685–693
  21. Chaplin DJ, Durand RE, Olive PL. Acute hypoxia in tumors: implications for modifiers of radiation effects. Int. J. Radiat. Oncol. Biol. Phys. 1986;12:1279–1282
  22. Papp-Szabo E, Josephy PD, Coomber BL. Microenvironmental influences on mutagenesis in mammary epithelial cells. Int. J. Cancer. 2005;116:679–685
  23. Shahrzad S, Quayle L, Stone C, Plumb C, Shirasawa S, Rak JW, et al. Ischemia-induced K-ras mutations in human colorectal cancer cells: role of microenvironmental regulation of MSH2 expression. Cancer Res. 2005;65:8134–8141
  24. Chen J, Shinkai Y, Young F, Alt FW. Probing immune functions in RAG-deficient mice. Curr. Opin. Immunol. 1994;6:313–319
  25. Alvarez-Tejado M, Naranjo-Suarez S, Jiménez C, Carrera AC, Landázuri MO, del Peso L. Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis. J. Biol. Chem. 2001;276:22368–22374
  26. Pelicano H, Xu RH, Du M, Feng L, Sasaki R, Carew JS, et al. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J. Cell Biol. 2006;175:913–923
  27. Lechanteur C, Jacobs N, Greimers R, Benoît V, Deregowski V, Chariot A, et al. Low daunomycin concentrations protect colorectal cancer cells from hypoxia-induced apoptosis. Oncogene. 2005;24:788–1793
  28. Kim M, Park SY, Pai HS, Kim TH, Billiar TR, Seol DW. Hypoxia inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by blocking Bax translocation. Cancer Res. 2004;64:4078–4081
  29. Anderson KM, Jajeh J, Guinan P, Rubenstein M. In vitro effects of dichloroacetate and CO2 on hypoxic HeLa cells. Anticancer Res. 2009;29:4579–4588
  30. Lingohr MK, Thrall BD, Bull RJ. Effects of dichloroacetate (DCA) on serum insulin levels and insulin-controlled signaling proteins in livers of male B6C3F1 mice. Toxicol. Sci. 2001;59:178–184
  31. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K, et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J. Biol. Chem. 2002;277:21843–21850
  32. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29–39
  33. Bates RC, Edwards NS, Burns GF, Fisher DE. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res. 2001;61:5275–5283
  34. Samudio I, Fiegl M, Andreeff M. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res. 2009;69:2163–2166
  35. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;92:464–468
  36. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468–472
  37. Yu F, White SB, Zhao Q, Lee FS. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc. Natl. Acad. Sci. USA. 2001;98:9630–9635
  38. Kato M, Li J, Chuang JL, Chuang DT. Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545 dichloroacetate and radicicol. Structure. 2007;15:992–1004
  39. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3:177–185
  40. Kim JY, Ahn HJ, Ryu JH, Suk K, Park JH. BH3-only protein Noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1alpha. J. Exp. Med. 2004;199:113–124
  41. Greijer AE, van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J. Clin. Pathol. 2004;57:1009–1014
  42. Malhotra R, Tyson DW, Rosevear HM, Brosius 3rd FC. Hypoxia-inducible factor-1alpha is a critical mediator of hypoxia induced apoptosis in cardiac H9c2 and kidney epithelial HK-2 cells. BMC Cardiovasc. Disord. 2008;8:9;(Apr 30)
  43. Stacpoole P, Kerr D, Barnes C, Bunch S, Carney P, Fennell E, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics. 2006;117:1519–1531
  44. Kaufmann P, Engelstad K, Wei Y, Jhung S, Sano M, Shungu D, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized controlled clinical trial. Neurology. 2006;66:324–330
  45. Stacpoole PW, Harman EM, Curry SH, Baumgartner TG, Misbin RI. Treatment of lactic acidosis with dichloroacetate. N. Engl. J. Med. 1983;309:390–396
  46. Tsai WH, DeAngelo AB. Responsiveness of hepatocytes from dichloroacetic acid or phenobarbital treated mice to growth factors in primary culture. Cancer Lett. 1996;99:177–183
  47. Armstrong D, Cameron RG. Comparison of liver cancer and nodules induced in rats by deoxycholic acid diet with or without prior initiation. Cancer Lett. 1991;57:153–157
  48. Robinson M, Bull RJ, Olson GR, Stober J. Carcinogenic activity associated with halogenated acetones and acroleins in the mouse skin assay. Cancer Lett. 1989;48:197–203
  49. Caldwell JC, Keshava N. Key issues in the modes of action and effects of trichloroethylene metabolites for liver and kidney tumorigenesis. Environ. Health Perspect. 2006;114:1457–1463

PII: S0304-3835(10)00251-X

doi: 10.1016/j.canlet.2010.04.027

Cancer Letters
Volume 297, Issue 1 , Pages 75-83 , 1 November 2010

Article Tools

* Image Usage & Resolution